CClinicalTrials.gg
Not yet recruitingNCT07046312Updated Jul 1, 2025

Right Ventricular Strain in Detecting Subclinical Right Ventricular Systolic Dysfunction in Psoriatic Arthritis Patients: Relation to Serum Endostatin Level

An observational study in Psoriatic Arthritis (PsA) and Subclinical Right Ventricular Systolic Dysfunction, sponsored by Ain Shams University. Not yet recruiting at 1 site in Egypt. Open to participants aged 20 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-01.

Sponsored by Ain Shams University · Observational

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
60
Ages
20 Years to 50 Years
Sex
All
01

Study summary

The aim is to assess early right ventricular systolic dysfunction in psoriatic arthritis patients using RV strain echocardiography

Read the detailed description

Previous studies evaluated RV strain for detection of subclinical RV affection due to PAH in systemic lupus erythematosus. However , to our knowledge , the study of RV strain and its possible association with serum endostatin to detect subclinical right ventricular systolic dysfunction and its relation to PAH in PsA patient is still a novel. Our aim is to assess early right ventricular systolic dysfunction in psoriatic arthritis patients using RV strain Echocardiography.

To evaluate serum endostatin as an objective biomarker for Pulmonary arterial hypertension.

02

Conditions studied

  • Psoriatic Arthritis (PsA)
  • Subclinical Right Ventricular Systolic Dysfunction

Browse trials for

03

In context

Arthritis, Psoriatic

579 studies on the registry are indexed under Arthritis, Psoriatic; 132 are open to participants now.

This study's planned enrollment of 60 is below the median of 300 across 235 observational studies indexed under Arthritis, Psoriatic.

Browse Arthritis, Psoriatic studies →

Lead sponsor

Ain Shams University is the lead sponsor of 1,876 studies on the registry; 423 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

30 patients with PsA and 30 matched healthy controls

Inclusion criteria

  • Psoriatic arthritis patients according to CASPAR criteria
  • Psoriatic arthritis patients without overt cardiovascular symptoms
  • Patients with age between 20 to 50 years of age

Exclusion criteria

Exclusion Criteria:

  • Other systemic autoimmune diseases
  • Patients with a history of known valvular disease, atrial fibrillation or any other arrhythmia , heart failure, ischemic cardiomyopathy severe obstructive pulmonary diseases and metabolic syndrome.
  • Patients with medical disorders as renal, congenital heart diseases, hematological disorders and cancer patients.
  • Patients taking certain drugs that have been confirmed to be risk factors for PAH such as appetite suppressant intake drugs (aminorex, fenfluramine derivatives and benfluorex) and chemotherapeutic agents.
  • Family history of myocardial infarction, cerebrovascular disease or sudden death before the age of 65y in females and 55 y in males.
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
60 participants (estimated)
Patient registry
No

Groups and cohorts

  • Control

    30 control group matched as regards BMI, age and sex will be subjected to transthoracic echo and measuring serum endostatin level.

  • Cases of Psoriatic arthritis patients

    30 PsA patients will be subjected to transthoracic echo, measuring serum endostatin level and modified composite psoriatic disease activity index

06

What researchers measure

Primary outcomes

  1. Detecting subclinical right ventricular systolic dysfunction in PsA patients

    Detecting subclinical right ventricular systolic dysfunction in PsA using 2D strain transthoracic echo and its relation to serum endostatin level

    Time frame: Up to 24 months

07

Study locations

1 site
  • Ain Shams University
    Cairo, Abbassia 00202, Egypt
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07046312
Lead sponsor
Ain Shams University
Responsible party
Sponsor
First posted
Jul 1, 2025
Start date
Jul 2025 (estimated)
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Jul 1, 2025

Study contacts

Dina Maamoun ElHadba, MSc Ain Shams University
Contact
DinaElhadba@med.asu.edu
01006780166

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion